Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention

AIDS Patient Care and STDs

Volumn 26, Issue 7, 2012, Pages 395-405

  White, Jaclyn M ^a   Mimiaga, Matthew J ^a,b,c   Krakower, Douglas S ^d   Mayer, Kenneth H ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MICROBICIDE;

ADULT; ARTICLE; ATTITUDE TO HEALTH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; EDUCATION PROGRAM; FEMALE; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PHYSICIAN ATTITUDE; UNITED STATES; UNSPECIFIED SIDE EFFECT; WORK EXPERIENCE;

ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; INTERNET; MALE; MASSACHUSETTS; PHYSICIANS; POST-EXPOSURE PROPHYLAXIS; QUESTIONNAIRES;

EID: 84864719203     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2012.0030     Document Type: Article

References (37)

1. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS ONE 2011;6:e17502.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of Tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
4. Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K. Packaging PrEP to prevent HIV: An integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr 2010;55:8-13.
5. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee S-J, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: A mixed methods study. AIDS Patient Care STDS 2012;26:87-94.
6. Myers GM, Mayer KH. Oral pre-exposure anti-HIV prophylaxis for high-risk U.S. populations: Current considerations in light of new findings. AIDS Patient Care STDS 2011;25:63-71.
7. Supervie V, Barrett M, Kahn JS, et al. Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: Predicting HIV transmission and resistance. Sci Rep 2011;1:185.
8. van de Vijver DA, Boucher CA. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. Curr Opin Infect Dis 2010;23:621-627.
9. Supervie V, García-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci 2010;107:12381-12386.
10. Grodensky C, Golin C, Boland M, Patel S, Quinlivan E, Price M. Translating concern into action: HIV care providers' views on counseling patients about HIV prevention in the clinical setting. AIDS Behav 2008;12:404-411.
11. Ewing GB, Selassie AW, Lopez CH, McCutcheon EP. Selfreport of delivery of clinical preventive services by U.S. physicians: Comparing specialty, gender, age, setting of practice, and area of practice. Am J Prev Med 1999;17:62-72.
12. Barton Laws M, Bradshaw Y, Safren S, et al. Discussion of sexual risk behavior in HIV care is infrequent and appears ineffectual: A mixed methods study. AIDS Behav 2011;15: 812-822.
13. Drainoni ML, Dekker D, Lee-Hood E, Boehmer U, Relf M. HIV medical care provider practices for reducing high-risk sexual behavior: Results of a qualitative study. AIDS Patient Care STDS 2009;23:347-356.
14. Kerr SH, Valdiserri RO, Loft J, et al. Primary care physicians and their HIV prevention practices. AIDS Patient Care STDS 1996;10:227-235.
15. Makadon HJ, Silin JG. Prevention of HIV infection in primary care: Current practices, future possibilities. Ann Intern Med 1995;123:715-719.
16. Rosengarten M, Michael M. The performative function of expectations in translating treatment to prevention: The case of HIV pre-exposure prophylaxis, or PrEP. Soc Sci Med 2009;69:1049-1055.
17. Eaton L, Kalichman S. Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007;4:165-172.
18. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009;48:806-815.
19. WHO. Report of a consultation: Preparing for pre-exposure prophylaxis (PrEP) results: From research to implementation. 2009.
20. Kim S, Becker S, Dieffenbach C, et al. Planning for pre-exposure prophylaxis to prevent HIV transmission: Challenges and opportunities. J Int AIDS Soc 2010;13;24.
21. Liu AY, Grant RM, Buchbinder SP. Preexposure Prophylaxis for HIV. JAMA 2006;296:863-865.
22. Portner Novelli. ConsumerStyles Survey. Washington, DC 2009.
23. Portner Novelli. HealthStyles Survey.Washington, DC 2009.
24. Portner Novelli. DocStyles Survey. Washington, DC 2009.
25. Mimiaga MJ, Goldhammer H, Belanoff C, Tetu AM, Mayer KH. Men who have sex with men: Perceptions about sexual risk, HIV and sexually transmitted disease testing, and provider communication. Sex Transm Dis 2007;34:113-119.
26. Mayer KH, Mimiaga MJ, Cohen D, Grasso C, Bill R. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr 2008;47:494-499.
27. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: Limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009;50:77-83.
28. SurveyMonkey.com LLC. Palo Alto, California: www .surveymonkey.com.
29. Mayer KH, Mimiaga MJ, VanDerwarker R, Goldhammer H, Bradford JB. Fenway Community Health's model of integrated, community-based LGBT care, education, and research the health of sexual minorities. In: Meyer IH, Northridge ME, eds: Springer US; 2007, pp. 693-715.
30. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. www .OpenEpi.com, 2011.
31. Hayden EC. HIV drug-prevention strategy carries risks. Nature 2011;476:260-261.
32. Leibowitz AA, Parker KB, Rotheram-Borus MJ. A US policy perspective on oral preexposure prophylaxis for HIV. Am J Public Health 2011/06/01 2011;101:982-985.
33. AIDS Vaccine Advocacy Coalition. Summary from the AVAC Think Tank on PrEP Financing in the US. 2009; http://www.avac.org/ht/d/sp/a/GetDocumentAction/i/ 3529. Accessed March 2, 2012.
34. Baeten J, Celum C, Partners PrEP Study Team. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: The Partners PrEP Study [abstract MOAX0106]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention Rome, Italy 2011.
35. Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: Results from the TDF2 study [abstract WELBC01]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy 2011.
36. Centers for Disease Control and Prevention. Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 2011; 60:65-68.
37. Krakower DS, Rosenberger JG, Novak DS, Mimiaga MJ, Mitty JA, Mayer KH. Patient-provider communication around sexual behaviors: Potential barriers to PrEP among MSM engaged in on-line networking [abstract 1686]. National HIV Prevention Conference. Atlanta, GA 2011.